.jpg)
Worse Outcomes With Transformed Indolent Lymphomas Versus De Novo DLBCL
These investigators used SEER data to compare the outcomes of transformed indolent non-Hodgkin lymphomas with de novo DLBCL at a population level, a situation for which little data exist.
In DLBCL, a Molecular Signature Predicts Primary Treatment Resistance
These investigators assessed the potential benefit of a high-risk signature to evaluate the molecular drivers of primary treatment resistance in patients with DLBCL.